Bioasis Engages With The FDA…Here’s What It Means

This week Bioasis heard back from the FDA on written questions they had submitted. These questions concern their lead investigational candidate xB3-001 and its...

Bioasis Announces FDA Response to Pre-IND Submission

Tailwinds' Take: Positive in that the timeline for development appears to be unchanged post the meeting, so that implies there were no significant issues...

Bioasis Announces Allowances of Patent Applications in the U.S. and Europe Relating to xB3...

Tailwinds' Take: this is a nice announcement, securing more IP around this platform technology. We remain intrigued by the Company, especially at this valuation,...

Markets Trade Down In May…June Preview

I'm not sure why, but it seems that every time I feel the Tailwinds' Portfolio is poised for big gains, the market enters a...

Bioasis Appoints Mario Saltarelli as Non-Executive Director of the Board of Directors

GUILFORD, Conn.–(Business Wire)– Bioasis Technologies, Inc . (OTCQB:BIOAF; TSX.V:BTI), ), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3 TM platform technology for the delivery of therapeutics across the...

Bioasis Announces Closing of Previously Disclosed Private Placement

Tailwinds' Take: Obviously, this cash was needed and will not suffice them for long. We would like to see just how much director and...

Bottom Fishing…

One of my favorite shows to watch on airplanes used to be The Deadliest Catch. This real life drama portrays a group of Alaskan king...

Bioasis Announces Private Placement

Tailwinds' Take: The Company needed this cash infusion rather desperately. I believe that management participated in the transaction. The technology is solid, but they...

Bioasis Appoints Dr. Deborah Rathjen as President & Chief Executive Officer

Tailwinds' Take: while this news comes suddenly and will likely cause some selling in the stock, we view it as constructive. Mark Day has...

Bioasis Announces Agreement With Leading Pharmaceutical Company for Pre-Clinical Research Using the xB3 Platform...

Tailwinds' Take: Bioasis appears to have done the necessary pre-clinical work to attract interest from partners. While still early stage, it's apparent that the...

Tailwinds Top 8 Surprises for 2019

Every year for the past 36 years, Byron Wien has put out a list of “Top 10 Surprises” for the...

Bioasis to Present at Investor & Industry Conferences in January 2019

Tailwinds' Take: having emerged from their silent period, Bioasis appears to be very excited about the data they are generating as they...

Bioasis Appoints Dr. Deborah A. Rathjen as Executive Chair of the Board of Directors

GUILFORD, Conn.–(Business Wire)– Bioasis Technologies Inc. (TSX.V:BTI; OTCQB:BIOAF) (the “Company” or “Bioasis”), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3 TM  platform technology for the delivery of...

What To Put In Your Stockings: December Preview

This weekend we'll be hanging our stockings on the mantel. Come Christmas morning, they'll be lying on the floor, overflowing with presents. At least,...

Bioasis Announces Positive Results from Peripheral Whole-Body PET/CT Scan Study in Non-Human Primates with...

Tailwinds' Take: this long awaited news is significant for Bioasis and should spark relief in the shares. Expect to see the Company move towards...

October Review, Earnings Preview

October has a reputation for being a bad month to own stocks. For the current generation of investors, this reputation was earned primarily from...

Bioasis Announces xB3 ™ Platform Technology Licensing Agreement with Prothena

Tailwinds' Take: a long anticipated licensing deal is likely a major sigh of relief for shares of BIOAF. While small in size, a $1M...

Bioasis Announces Investor Relations Service Agreement with Stern IR

GUILFORD, Conn.–(Business Wire)– Bioasis Technologies, Inc. (TSX.V:BTI; OTCQB:BIOAF), a biopharmaceutical company developing its proprietary xB3 ™ platform technology for the delivery of therapeutics across the blood-brain barrier (BBB)...

Bioasis Announces Closing of Previously Disclosed Private Placement

Bioasis Technologies (TSX.V:BTI; OTCQB:BIOAF) (“Bioasis” or the “Company”), a biopharmaceutical company developing its xB3 TM proprietary platform technology for the delivery of therapeutics across the blood-brain barrier...

Bioasis Announces Positive Results from a Microdialysis Study Showing Lead Investigational Candidate xB3 ™-001...

Tailwinds' Take: This is excellent progress. If it translates into human data, a decent probability, it could be huge. Once they get properly funded...
DFC Advisory Services LLC (dba Tailwinds Research) is a registered investment adviser. Information presented is for educational purposes only and does not intend to make an offer or solicitation for the sale or purchase of any specific securities, investments, or investment strategies. Investments involve risk and unless otherwise stated, are not guaranteed. Be sure to first consult with a qualified financial adviser and/or tax professional before implementing any strategy discussed herein. Past performance is not indicative of future performance.